Epanova® for Lowering Very High Triglycerides II (EVOLVE II)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 379 participants.

Also called NCT02009865

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 379 participants (enrolled count) (from the registry)
Sponsor
  • AstraZeneca Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02009865
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Canada, Czechia, Denmark, Hungary, Netherlands, Russia (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02009865. Randomized; double masking; primary purpose treatment. Start 2013-12-16 (actual); primary completion 2014-12-23 (actual). Results posted on 2016-01-15.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Epanova® for Lowering Very High Triglycerides II (EVOLVE II)
Acronym
EVOLVEII
Condition
Hypertriglyceridemia
Intervention (Drug)
Epanova
Intervention (Drug)
Olive Oil
Lead sponsor
AstraZeneca (class: industry)

Record details

Record id
cardio:ct-nct02009865
Content hash
52805bed53ab5c9ad2ca531f9851449482959d6b0f962ef79d97e2d64c045a08